The Manufacturers Life Insurance Company Grows Stake in DaVita Inc. (NYSE:DVA)

The Manufacturers Life Insurance Company boosted its stake in DaVita Inc. (NYSE:DVA) by 0.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,244 shares of the company’s stock after buying an additional 150 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.05% of DaVita worth $6,269,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. 8 Knots Management LLC acquired a new position in shares of DaVita during the fourth quarter valued at approximately $89,504,000. Doma Perpetual Capital Management LLC acquired a new position in DaVita in the 4th quarter valued at $53,076,000. Harvard Management Co. Inc. purchased a new position in DaVita in the 2nd quarter valued at $55,115,000. Lazard Asset Management LLC boosted its stake in DaVita by 147.3% during the 1st quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock worth $35,460,000 after purchasing an additional 153,008 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of DaVita by 2.4% during the fourth quarter. Vanguard Group Inc. now owns 6,320,740 shares of the company’s stock worth $662,161,000 after buying an additional 145,711 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Stock Up 1.0 %

Shares of NYSE:DVA opened at $160.69 on Friday. The company has a market capitalization of $14.09 billion, a price-to-earnings ratio of 18.26, a PEG ratio of 0.91 and a beta of 0.87. DaVita Inc. has a 12-month low of $71.51 and a 12-month high of $166.04. The business has a 50-day moving average price of $152.14 and a 200 day moving average price of $142.92. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The business had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.15 billion. During the same period in the previous year, the firm earned $2.08 EPS. The business’s revenue was up 6.2% on a year-over-year basis. Sell-side analysts expect that DaVita Inc. will post 9.99 EPS for the current year.

Analyst Upgrades and Downgrades

DVA has been the topic of several research reports. UBS Group raised their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Truist Financial boosted their price objective on DaVita from $150.00 to $165.00 and gave the stock a “hold” rating in a research note on Tuesday, August 20th. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. TD Cowen boosted their price target on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Finally, Bank of America raised their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, DaVita presently has an average rating of “Hold” and an average price target of $157.00.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at $138,284,666.75. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the sale, the chief executive officer now owns 837,835 shares of the company’s stock, valued at $138,284,666.75. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 173,482 shares of company stock valued at $27,387,069. Corporate insiders own 2.00% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.